mTOR Signaling and Cancer Progression
Abnormal Proliferation
General Transcription Factors
Tumor Immunotherapy
lncRNA - Long Non-coding RNAs
The Retinoblastoma Gene
Joyce Chen1,2,3,4, Isaac F López-Moyado5,6,7, Hyungseok Seo5
1Division of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA. jchen@lji.org.

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
10:29Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
PubMed で要約を見る
固体腫瘍を標的とするキメリック抗原受容体 (CAR) T細胞は,NR4A転写因子により機能不全する. これらのNR4A因子を抑制することで,CAR T細胞の機能を回復させ,がんの免疫療法を改善することができます.
科学分野:
背景:
研究 の 目的:
主な方法:
主要な成果:
結論: